To explore geographical variation and trends in the prescription of prostaglandin analogs (PGAs) for glaucoma across Clinical Commissioning Groups (CCGs) in England from 2019 to 2024, highlighting its significance for patient care.
Key Findings:
A significant proportion of glaucoma spending in England is attributed to branded and preservative-free (PF) medications.
Cost-effective prescribing practices are lacking, with potential savings of over £30 million annually by switching to generic options.
Geographical variations in PGA prescriptions were observed across CCGs, indicating disparities in adherence to clinical guidelines, with specific percentages or figures to illustrate these variations.
Interpretation:
The study highlights the need for improved cost-effective prescribing practices for PGAs in glaucoma management, emphasizing the importance of adhering to clinical guidelines to optimize NHS resources and improve patient outcomes.
Limitations:
Data for some branded preparations were not available at the time of the study, which may limit the comprehensiveness of the findings.
The analysis relied on prescribing data, which may not fully capture patient adherence or clinical outcomes, potentially affecting the study's conclusions.
Conclusion:
The findings underscore the necessity for targeted interventions to enhance the cost-effectiveness of glaucoma treatment and ensure alignment with clinical guidelines across England, addressing the identified disparities.
